Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.
作者信息
Gowin Krisstina, Coakley Maria, Kosiorek Heidi, Mesa Ruben
机构信息
Mayo Clinic Arizona, Department of Hematology, Scottsdale, AZ, USA.
Department of Medical Oncology, Cork University Hospital, Wilton, Ireland.
出版信息
Haematologica. 2016 Oct;101(10):e405-e406. doi: 10.3324/haematol.2016.149013. Epub 2016 Jun 27.
Abstract
摘要
相似文献
1
Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.真性红细胞增多症/原发性血小板增多症后骨髓纤维化患者应用原发性骨髓纤维化预后评分的差异。
Haematologica. 2016 Oct;101(10):e405-e406. doi: 10.3324/haematol.2016.149013. Epub 2016 Jun 27.
2
Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化是1种、2种还是3种疾病？
Leukemia. 2021 Jul;35(7):1890-1893. doi: 10.1038/s41375-021-01254-w. Epub 2021 Apr 28.
3
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).慢性骨髓增殖性疾病（MPD）、原发性血小板增多症（ET）、真性红细胞增多症（PV）和慢性特发性骨髓纤维化（CIMF）的现行诊断标准。
Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21.
4
Diagnostic approaches to polycythemia vera in 2004.2004年真性红细胞增多症的诊断方法
Expert Rev Mol Diagn. 2004 Jul;4(4):495-502. doi: 10.1586/14737159.4.4.495.
5
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.真性红细胞增多症、特发性血小板增多症和原发性骨髓纤维化的预后因素和模型。
Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S25-7. doi: 10.1016/j.clml.2011.01.002. Epub 2011 Apr 29.
6
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.真性红细胞增多症后和原发性血小板增多症后骨髓纤维化患者的表型和基因型的性别效应：MYSEC项目的结果
Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x.
7
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.世界卫生组织真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化的修订诊断标准：一项替代建议。
Blood. 2008 Jul 15;112(2):231-9. doi: 10.1182/blood-2007-12-128454. Epub 2008 Apr 9.
8
Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.JAK2 V617F等位基因负荷的定量评估：外周血和骨髓中的水平相当
Leukemia. 2008 Jan;22(1):194-5. doi: 10.1038/sj.leu.2404861. Epub 2007 Jul 12.
9
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.JAK2 V617F时代真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化的诊断与管理
Clin Adv Hematol Oncol. 2009 May;7(5):334-42.
10
Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis.原发性血小板增多症与伴有显著血小板增多的真性红细胞增多症的鉴别。
Am J Hematol. 1987 Jun;25(2):191-201. doi: 10.1002/ajh.2830250209.
引用本文的文献
1
Myelofibrosis and allogeneic transplantation: critical points and challenges.骨髓纤维化与异基因移植：关键点与挑战
Front Oncol. 2024 Jun 20;14:1396435. doi: 10.3389/fonc.2024.1396435. eCollection 2024.
2
Real-World Electronic Medical Records Data Identify Risk Factors for Myelofibrosis and Can Be Used to Validate Established Prognostic Scores.真实世界电子病历数据可识别骨髓纤维化的风险因素，并可用于验证既定的预后评分。
Cancers (Basel). 2024 Apr 5;16(7):1416. doi: 10.3390/cancers16071416.
3
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future.骨髓纤维化与生存预后模型：过去与未来之间的历程
J Clin Med. 2023 Mar 11;12(6):2188. doi: 10.3390/jcm12062188.
4
CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis.CD34+ 阳性造血干细胞移植联合清髓性预处理方案治疗晚期骨髓纤维化患者。
Bone Marrow Transplant. 2022 Jul;57(7):1101-1107. doi: 10.1038/s41409-022-01684-9. Epub 2022 Apr 28.
5
Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea.芦可替尼治疗骨髓纤维化患者的临床疗效：韩国一项基于全国人群的研究
J Clin Med. 2021 Oct 18;10(20):4774. doi: 10.3390/jcm10204774.
6
Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.近年来，分子分析在为真性红细胞增多症患者的诊断和预后提供信息方面的应用进展。
Int J Mol Sci. 2021 May 10;22(9):5042. doi: 10.3390/ijms22095042.
7
MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.骨髓增殖性肿瘤（MPN）：疾病起始、进展和转化的分子驱动因素及其对治疗的影响。
Cells. 2020 Aug 14;9(8):1901. doi: 10.3390/cells9081901.
8
Survival following allogeneic transplant in patients with myelofibrosis.异基因移植后骨髓纤维化患者的生存情况。
Blood Adv. 2020 May 12;4(9):1965-1973. doi: 10.1182/bloodadvances.2019001084.
9
Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.原发性骨髓纤维化后 ET 和后 PV 骨髓纤维化：与原发性骨髓纤维化相比预后的新进展。
Curr Hematol Malig Rep. 2018 Jun;13(3):173-182. doi: 10.1007/s11899-018-0453-y.
10
SOHO State-of-the-Art Update and Next Questions: MPN.SOHO最新进展及后续问题：骨髓增殖性肿瘤
Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):1-12. doi: 10.1016/j.clml.2017.11.008.
本文引用的文献
1
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.原发性骨髓纤维化中红细胞增多症后和血小板增多症后突变的流行病学和临床相关性：AGIMM 组 359 例患者的研究。
Am J Hematol. 2016 Jul;91(7):681-6. doi: 10.1002/ajh.24377. Epub 2016 May 11.
2
The evolution and clinical relevance of prognostic classification systems in myelofibrosis.骨髓纤维化中预后分类系统的演变及其临床相关性。
Cancer. 2016 Mar 1;122(5):681-92. doi: 10.1002/cncr.29842. Epub 2015 Dec 30.
3
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.CALR 和 ASXL1 基因突变在原发性骨髓纤维化中的分子预后：一项 570 例患者的国际研究。
Leukemia. 2014 Jul;28(7):1494-500. doi: 10.1038/leu.2014.57. Epub 2014 Feb 5.
4
Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage.纤维化期红细胞增多后骨髓纤维化与原发性骨髓纤维化之间的形态学和细胞遗传学差异。
Mod Pathol. 2013 Dec;26(12):1577-85. doi: 10.1038/modpathol.2013.109. Epub 2013 Jun 21.
5
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.DIPSS plus：一种改良的原发性骨髓纤维化动态国际预后评分系统，纳入了核型、血小板计数和输血状态的预后信息。
J Clin Oncol. 2011 Feb 1;29(4):392-7. doi: 10.1200/JCO.2010.32.2446. Epub 2010 Dec 13.
6
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.动态国际预后评分系统（DIPSS）可预测原发性骨髓纤维化进展为急性髓系白血病的情况。
Blood. 2010 Oct 14;116(15):2857-8. doi: 10.1182/blood-2010-06-293415.
7
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.基于骨髓纤维化研究与治疗国际工作组的一项研究的原发性骨髓纤维化新预后评分系统。
Blood. 2009 Mar 26;113(13):2895-901. doi: 10.1182/blood-2008-07-170449. Epub 2008 Nov 6.
8
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.一种预测真性红细胞增多症后骨髓纤维化患者生存情况的动态预后模型。
Blood. 2008 Apr 1;111(7):3383-7. doi: 10.1182/blood-2007-11-121434. Epub 2008 Jan 10.
9
Pathogenesis of myelofibrosis with myeloid metaplasia.伴有髓外化生的骨髓纤维化的发病机制。
J Clin Oncol. 2005 Nov 20;23(33):8520-30. doi: 10.1200/JCO.2004.00.9316.
10
Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.
Blood. 1996 Aug 1;88(3):1013-8.
Zotero 插件